Abstract
Insomnia is a heritable, highly prevalent sleep disorder, for which no sufficient treatment currently exists. Previous genome-wide association studies (GWASs) with up to 1.3 million subjects identified over 200 associated loci. This extreme polygenicity suggested many more loci to be discovered. The current study almost doubled the sample size to over 2.3 million individuals thereby increasing statistical power. We identified 554 risk loci (confirming 190 previously associated loci and detecting 364 novel), and capitalizing on this large number of loci, we propose a novel strategy to prioritize genes using external biological resources and information on functional interactions between genes across risk loci. Of all 3,898 genes naively implicated from the risk loci, we prioritize 289. For these, we find brain-tissue expression specificity and enrichment in specific gene-sets of synaptic signaling functions and neuronal differentiation. We show that the novel gene prioritization strategy yields specific hypotheses on causal mechanisms underlying insomnia, which would not fully have been detected using traditional approaches.
Competing Interest Statement
P.N., X.W., D.H, and members of the 23andMe Research Team are employees of 23andMe, Inc., and hold stock or stock options in 23andMe.
Funding Statement
D.P. was funded by The Netherlands Organization for Scientific Research (NWO VICI 453-14-005), NWO Gravitation: BRAINSCAPES: A Roadmap from Neurogenetics to Neurobiology (Grant No. 024.004.012), and a European Research Council advanced grant (Grant No, ERC-2018-AdG GWAS2FUNC 834057). E.J.W.V.S. was funded by the European Research Council (ERC-ADG-2014-671084 INSOMNIA). The research has been conducted using the UK Biobank Resource (application no. 16406). The research was based in part on data from the Million Veteran Program - Office of Research and Development, Veterans Health Administration - supported by awards CSP #575B and Merit 1I01CX001849.e.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NA
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The GWAS summary statistics for the 23andMe data set will be made available through 23andMe to qualified researchers under an agreement with 23andMe that protects the privacy of the 23andMe participants. Please visit https://research.23andme.com/collaborate/#publication for more information and to apply to access the data.
